AnaptysBio Investor Relations Material

AnaptysBio Inc is a clinical-stage biotechnology company. It focuses on developing immunology therapeutics aimed at autoimmune and inflammatory diseases. The company's product pipeline includes several key antibody candidates like Imsidolimab, an anti-IL-36 receptor antibody for treating generalized pustular psoriasis, currently in Phase 3 trials. Another significant product is Rosnilimab, an anti-PD-1 agonist antibody designed to address T-cell driven inflammatory diseases. Additionally, ANB032, an anti-BTLA modulator antibody, is being developed for various human inflammatory diseases linked to immune cell dysregulation. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.